Do Psychedelics Actually Work for Depression, PTSD, and Addiction? What the Evidence Says

Psychedelic medicine has moved from the fringe into the mainstream, and the marketing is running well ahead of the data. I want to walk through what we actually know, because the headlines are doing a lot of heavy lifting.

What psychedelics actually do to your brain

Three brain functions get scrambled by classic psychedelics like psilocybin, LSD, and MDMA, all of which work on the serotonin 2A receptor. Ketamine is the exception. It is a dissociative anesthetic, not a hallucinogen, and it works on a different receptor.

The first function is reality testing. Your brain constantly checks incoming stimuli against what it knows about the world. That system shuts down during dreaming, which is why a goblin bursting through your door feels normal in a dream. Psychedelics shut it down too. The tree melting in front of you stops being a problem your brain wants to flag.

The second is salience. Your brain tags experiences with a level of meaning so it knows what to remember and what to ignore. Psychedelics crank salience up across the board. A banal moment on the couch suddenly feels enormous, and people often interpret that cognitive dissonance as the presence of something larger than themselves. Notably, the same loss of reality testing plus heightened salience shows up in paranoid schizophrenia, which is why the early psychedelics were called psychotomimetics.

The third, and probably most relevant to therapy, is neuroplasticity. Serotonin 2A activity may increase the brain's ability to form new connections. The leading hypothesis is that the drug shakes things up and the integration work afterward, with a therapist, lets the brain rewire in a better configuration.

The evidence for mental health conditions

Start with PTSD. President Trump recently talked up ibogaine on Joe Rogan, citing an 80% to 90% reduction in depression and anxiety symptoms. The source is a 2024 Nature Medicine paper of 30 male veterans with mild traumatic brain injury treated with magnesium plus ibogaine. The improvements in PTSD, depression, and anxiety scales were genuinely large. About 28 of 30 went from moderate PTSD to minimal PTSD after a single dose. It is also not a randomized trial, there is no control group, and a separate ibogaine PTSD study showed weaker effects. One randomized ibogaine trial exists, and it was a safety study of dose, not efficacy.

Depression has the strongest data. A 2023 JAMA trial randomized 104 adults with major depressive disorder to a single 25 mg dose of psilocybin or 100 mg of niacin as a placebo, with 11 hours of psychological support around the dose. Depression scores dropped by 12 points, a clinically meaningful difference. Sustained response at day 43 was 42% in the psilocybin arm versus 11% in the niacin arm. A separate NEJM trial compared psilocybin head-to-head with a standard SSRI and found no difference in the primary outcome, though some secondary outcomes favored psilocybin. So psilocybin looks roughly comparable to an SSRI, not dramatically better. A single dose with side effects up front may still beat daily pills with chronic side effects for some people.

For anxiety, the data are thinner. A 2016 Journal of Psychopharmacology study of high-dose psilocybin in patients with cancer-related anxiety and depression showed improvements in anxiety, depression, and demoralization. If you are an already anxious person, jumping into an experience where the walls are melting may not be the right first move.

For addiction, ibogaine has open-label data only. A 2018 Frontiers in Pharmacology study of 191 people using opioids or cocaine showed reduced withdrawal symptoms and cravings at one month after a single dose. No randomized trial exists. Psilocybin has better evidence in alcohol use disorder, with randomized data showing a reduction in heavy drinking days versus a diphenhydramine control.

What about healthy people who are just curious?

A recent study gave 28 psychedelic-naive, otherwise healthy adults either 25 mg or 1 mg of psilocybin, then ran EEG and functional MRI a month later. Twenty-seven of 28 rated the high dose as the single most unusual conscious state of their lives. EEG showed an acute drop in alpha power, which is roughly the brain's self-control lid, and a big increase in EEG complexity. One month later, the functional MRI did not show dramatic structural changes, but psychological well-being was significantly higher in the 25 mg group, and people who reported more insight the day after had better well-being a month out.

Whether that means something fundamental changed, or whether it is the afterglow of a memorable experience the way you feel good after a great vacation, the study cannot tell you.

Microdosing, by contrast, looks unimpressive. A true microdose is supposed to be too low to produce psychedelic effects. The data suggest some improvement in well-being on the day of dosing, but it does not persist. That may be a placebo effect, or it may be the rough equivalent of having a glass of wine.

The placebo problem and the safety problem

You cannot really blind a psychedelic trial. People know when the walls are melting. That makes everything harder to interpret, especially for outcomes like depression and PTSD where the placebo effect is itself a brain phenomenon. Researchers have tried niacin, diphenhydramine, and active SSRIs as controls. None of them are perfect.

On safety: these compounds raise blood pressure modestly. People with schizophrenia or a strong family history should not use them. Most of these drugs are Schedule I in the US, which makes them both illegal outside research settings and very hard to study. Ketamine is Schedule III and gets used routinely in clinical medicine, including for setting children's broken bones. Street psychedelics are frequently adulterated. LSD is roughly 1,000 times more potent than psilocybin at the serotonin 2A receptor, and a real dose is the size of a grain of salt, so you are trusting whoever made the blotter paper. Some mushrooms look like other mushrooms, and some of those will kill you.

Bottom line

The mental health data for psychedelics, particularly psilocybin for depression and ibogaine or MDMA for PTSD, are genuinely promising. They are not yet good enough to overturn standard care, and most of the trials are small, short, and hard to blind. Rescheduling these drugs would let researchers run the large, preregistered, randomized trials we need. For healthy adults, the case is curiosity, not Wellness optimization. Microdosing does not appear to do much. And buying psychedelics on the street is a bad idea on multiple fronts.

Here's our discussion from the episode:

I covered this in depth on Wellness, Actually. Listen below.

Wellness, Actually Podcast

"What's the deal with psychedelics?" — Listen to the full episode, including the week's health news and listener Q&A.